DESYREL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Desyrel, and what generic alternatives are available?
Desyrel is a drug marketed by Pragma and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-three countries.
The generic ingredient in DESYREL is trazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the trazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desyrel
A generic version of DESYREL was approved as trazodone hydrochloride by APOTEX on March 25th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DESYREL?
- What are the global sales for DESYREL?
- What is Average Wholesale Price for DESYREL?
Summary for DESYREL
| International Patents: | 32 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Clinical Trials: | 14 |
| Patent Applications: | 1,664 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DESYREL |
| What excipients (inactive ingredients) are in DESYREL? | DESYREL excipients list |
| DailyMed Link: | DESYREL at DailyMed |
Recent Clinical Trials for DESYREL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute on Aging (NIA) | Phase 2 |
| Johns Hopkins University | Phase 2 |
| University of Southern California | Phase 4 |
US Patents and Regulatory Information for DESYREL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-004 | Nov 7, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-003 | Mar 25, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DESYREL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-003 | Mar 25, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Pragma | DESYREL | trazodone hydrochloride | TABLET;ORAL | 018207-003 | Mar 25, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DESYREL
See the table below for patents covering DESYREL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2008285779 | Trazodone and trazodone hydrochloride in purified form | ⤷ Sign Up |
| Poland | 2178850 | ⤷ Sign Up | |
| Netherlands | 8001700 | ⤷ Sign Up | |
| Mexico | 2010001094 | TRAZODONA Y HIDROCLORURO DE TRAZODONA EN FORMA PURIFICADA. (TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM.) | ⤷ Sign Up |
| Hungary | 191022 | COMPOSITE TABLET | ⤷ Sign Up |
| Denmark | 155566 | ⤷ Sign Up | |
| South Korea | 840002732 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
